Georgios Xylomenos
Overview
Explore the profile of Georgios Xylomenos including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
16
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kostaki E, Limnaios S, Adamis G, Xylomenos G, Chini M, Mangafas N, et al.
HIV Med
. 2022 Oct;
23(11):1143-1152.
PMID: 36258653
Objectives: HIV late presentation (LP) has been increasing in recent years in Europe. Our aim was to investigate the characteristics of LP in Greece using in addition to the traditional...
2.
Kostaki E, Gova M, Adamis G, Xylomenos G, Chini M, Mangafas N, et al.
Viruses
. 2020 Oct;
12(10).
PMID: 33086773
Our aim was to investigate the dispersal patterns and parameters associated with local molecular transmission clusters (MTCs) of subtypes A1 and B in Greece (predominant HIV-1 subtypes). The analysis focused...
3.
Kostaki E, Hodges-Mameletzis I, Magiorkinis G, Adamis G, Xylomenos G, Nikolopoulos G, et al.
Sex Transm Infect
. 2020 Jun;
97(3):232-237.
PMID: 32561553
Objectives: Subtypes A1 and B are the most prevalent HIV-1 clades in Greece. Subtype A1 epidemic is highly monophyletic and corresponds to transmissions that occurred locally. Our aim in this...
4.
Paraskevis D, Kostaki E, Gargalianos P, Xylomenos G, Lazanas M, Chini M, et al.
Genes (Basel)
. 2017 Nov;
8(11).
PMID: 29137167
The presence of human immunodeficiency virus type 1 (HIV-1) drug resistance among drug-naïve patients remains stable, although the proportion of patients with virological failure to therapy is decreasing. The dynamics...
5.
Paraskevis D, Zavitsanou A, Magiorkinis E, Gargalianos P, Xylomenos G, Lazanas M, et al.
J Int AIDS Soc
. 2014 Nov;
17(4 Suppl 3):19742.
PMID: 25397487
Introduction: The prevalence of drug resistance is approximately 10% in Europe and North America among newly infected patients. We aim to investigate the temporal patterns of resistance among drug naive...